Rafael Holdings (NYSE: RFL) ramps R&D spend, widens loss on $37.8M cash balance
Rafael Holdings (NYSE: RFL) reported a wider net loss of $16.2 million for the six months ended January 31, 2026, compared to $13.6 million in the prior year, primarily due to a significant increase in research and development expenses, which rose to $12.0 million from $2.3 million. The company's revenue increased to $451 thousand, driven by rental income and new product sales. With a cash balance of $37.8 million, Rafael Holdings anticipates having sufficient liquidity for at least the next 12 months as it continues to focus on advancing its lead drug candidate, Trappsol® Cyclo™, through a pivotal Phase 3 clinical trial.
JAN 12·Investing.com▲
Rafael Holdings elects directors, approves equity plan amendment at annual meeting
Rafael Holdings, Inc. (NYSE:RFL) held its annual meeting where shareholders elected directors, ratified CohnReznick LLP as their accounting firm, and approved an amendment to the company's 2021 Equity Incentive Plan. This amendment increases the shares of Class B common stock available for grant by 1,000,000. Additionally, the company recently issued warrants as part of its merger with Cyclo Therapeutics, which are now listed on NYSE American.
OCT 29·GlobeNewswire▲
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee ( DMC ) following their review of prespecified safety and ...
